Results 51 to 60 of about 72,840 (299)
Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
Brain Sciences, 2019 Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS).
Gloria Martí-Andrés +6 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) tracks disease severity in autoimmune encephalitis (AE), but no threshold for significant change exists. We aimed to determine the minimally clinically important difference (MCID) for CASE.
Yihui Goh +8 more
wiley +1 more source
Annals of Movement DisordersScapular dyskinesia, one of the rare forms of focal dyskinesia, is usually considered a peripheral induced movement disorder (PIMD), occurring in the background of previous trauma or surgery.
Anjali Chouksey, Ganeshgouda Majigoudra
doaj +1 more source
Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders - A case series [PDF]
, 2002 Atypical neuroleptics are increasingly used in the treatment of bipolar and schizoaffective disorders. Currently, numerous controlled short-term studies are available for clozapine, olanzapine, risperidone or quetiapine, but long-term data are still ...
Amann, B. +5 more
core +1 more source
CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao +7 more
wiley +1 more source
Frontiers in NeurologyDyskinesia-hyperpyrexia syndrome, a rare medical emergency in Parkinson's disease, is first described in 2010. It is characterized by severe continuous dyskinesia associated with rhabdomyolysis, hyperthermia and subsequent alteration of the mental state.
Xiangnan Du +3 more
doaj +1 more source
Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
Frontiers in Immunology, 2021 Dyskinesia is a serious complication of Parkinson’s disease during levodopa (L-DOPA) treatment. The pathophysiology of L-DOPA-induced dyskinesia (LID) is complex and not fully illuminated. At present, treatment of dyskinesia is quite limited.
Chang-Qing Zheng +5 more
doaj +1 more source
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease [PDF]
, 2003 Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-
Krack, P. +11 more
core +4 more sources
Frontiers in Neurology, 2022 BackgroundThe Unified Dyskinesia Rating Scale (UDysRS) evaluates dyskinesia in patients with Parkinson's disease (PD). A minimal clinically important change (MCIC)—the smallest change in a treatment outcome that a patient considers important—remains ...
Rajesh Pahwa +8 more
doaj +1 more source
Respiratory Organ‐on‐a‐Chip for Disease Modeling: From Architecture to Functional Integration
Advanced Healthcare Materials, EarlyView.Respiratory organ‐on‐a‐chip (ROC) models capture key mechanical and cellular cues of the human respiratory system, enabling quantitative dissection of disease mechanisms. This review links ROC architectures to disease modeling, functional integration, and commercialization, and proposes a decision framework that aligns model complexity with mechanistic
Jinzhuo Hu +4 more
wiley +1 more source